Foix-Alajouanine syndrome is an arteriovenous (AV) malformation of the spinal cord predominantly affecting the lower thoracic and/or lumbosacral levels; cervical cord involvement is rare. Findings include necrosis of the affected cord regions. Grey matter (as compared with white matter) structures are more severely involved. (See Etiology.)
Masses of enlarged, tortuous, thick-walled subarachnoid veins are observed overlying the surface of the cord (primarily on the posterior aspect). Smaller blood vessels with thickened fibrotic walls also are present within the affected spinal cord segments (see the image below). (See Workup.)
Foix and Alajouanine first described the syndrome in 2 young men (aged 29 y and 27 y), in 1926.  Historically eponymic, the syndrome now has many other names in the literature, including angiodysgenetic necrotizing myelopathy, subacute necrotizing myelopathy, and venous congestive myelopathy. 
Foix-Alajouanine syndrome is a rare entity. No specific statistics are available with regard to its frequency in the United States, but the condition is likely underdiagnosed.
Patients should be taught proper bladder and bowel care. Education regarding the identification of early symptoms and signs of disease recurrence also is required. Educate the patient’s family and/or caregiver about proper skin care and nutrition and about patient transfer requirements. (See Presentation.)
The etiology of Foix-Alajouanine syndrome is not well understood. Most patients have an AV fistula in the lower thoracic dura. One etiologic hypothesis is that the higher arterial pressure within the dura is transmitted to the spinal venous plexus via the intradural venous system, compromising perfusion and leading to infarction of the spinal cord parenchyma. Arterial blood originating from the dural fistula enters the venous system, increasing pressure and impairing normal drainage from the cord parenchyma. 
Thrombosis may occur, but not until late in the course of the disease. Venous stasis, not thrombosis, may be the primary cause of infarction. The preferential involvement of the distal cord is presumably due to orthostasis.
The onset in middle age suggests that the syndrome is acquired, in contrast to other vascular malformations, which are presumed to be congenital abnormalities, although the specificity for the spinal cord is not easily explained.
Foix-Alajouanine syndrome is a subacute disorder that gradually evolves over 1-5 years.  Affected patients initially are spastic but eventually develop flaccid paralysis of the limbs and may become wheelchair bound. Death can occur with terminal sepsis or other sequelae.
The prognosis is poor if treatment is not administered before neurologic deterioration occurs. Successful embolization and/or surgical interruption of the draining veins can halt the progression of symptoms and provide clinical improvement in many patients. Operations, if successful, are permanent modalities of treatment. After embolization, recanalization may occur, but this is rarely seen if the draining vein is filled with glue. 
Patients may suffer recrudescence of symptoms, lack of improvement, or rapid neurologic deterioration (eg, flaccid, areflexic paraplegia with complete loss of sensation below the lesion).
Angiographic examination contains an element of risk, especially in older patients; it may compromise local circulation, which can aggravate neurologic deficits. With regard to surgery, a fatal postoperative outcome is not uncommon.
The enlarged, abnormal veins are associated with dural AV shunts or fistulas, usually intradurally, but rarely extradurally.  These AV shunts are associated with reflux of arterial blood into the venous drainage of the cord. This leads to congestion of venous outflow and results in increased venous pressure in the affected regions of the spinal cord, often leading to ischemic injury. (See Etiology and Treatment.) [2, 5]
No recent data exists describing the incidence or prevalence of patients with or treated for Foix-Alajouanine Syndrome in the United States or across other countries. A retrospective study from 2001 in Germany estimated a prevalence of 5-10 cases per one million people in the general population, though this disease is probably underdiagnosed. 
Outcomes after diagnosis and treatment depend on factors such as the duration of symptoms, the pre-treatment disability, and the success of the procedure to close the fistula. Symptoms that generally improve after treatment are gait difficulties and muscle strength. Micturition, pain, and muscle spasms are symptoms that often do not respond as well. 
No data is currently available indicating if Foix-Alajouanine syndrome is more prevalent in specific ethnic/racial groups.
The male to female ratio for Foix-Alajouanine syndrome is approximately 5:1. 
What would you like to print?